Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals, Inc. (NRXP) announced a $2M underwritten public offering of its common stock at $3.30 per share. The offering includes an option for underwriters to purchase additional shares and is expected to close on April 19, 2024. Proceeds will be used for working capital, general corporate purposes, and possibly to repay debt.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 12:35 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Bio-Path Holdings, SINTX Techs, 23andMe Holding, Benitec Biopharma, Trevena, and Citius Pharma were among the gainers with notable percentage increases in their stock prices. Conversely, NRX Pharmaceuticals, Soligenix, Sonoma Pharmaceuticals, Mustang Bio, Dynatronics, and SeaStar Medical Holding were the losers, experiencing declines in their stock prices. SeaStar Medical specifically mentioned its Q4 earnings release two days ago.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 12:09 pm

Alcoa Corporation (NYSE:AA) shares rose in pre-market trading after reporting better-than-expected sales for Q1, despite a quarterly loss. Other stocks showed significant movement in pre-market trading, with notable gainers including Tian Ruixiang Holdings Ltd, MicroCloud Hologram Inc., and Smart for Life, Inc., among others. Losers included Planet Green Holdings Corp., Soligenix, Inc., and NRx Pharmaceuticals, Inc., which announced a public offering of common stock.

Portfolio Pulse from Priya Nigam

April 18, 2024 | 10:28 am

NRx Pharmaceuticals plans to sell shares of its common stock in a public offering, aiming to use the proceeds for working capital, general corporate purposes, initiating a national treatment protocol, safety database, and possibly repaying certain outstanding debt. No specific terms of the offering were disclosed.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:46 pm

NRx Pharmaceuticals released data indicating that in rodent models, their drug NRX-101 showed no impact on gut or vaginal flora. This finding is significant for the drug's safety profile, as it suggests that NRX-101 does not disrupt the microbiome, a common concern for new medications.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:35 pm

NRX Pharmaceuticals (NYSE:NRXP) has seen a significant increase in short interest, with the short percent of float rising 987.89% to 62.88% of all shares available for trading. This indicates a bearish market sentiment towards NRXP, as more traders are betting against the stock. However, an increase in short interest can sometimes be bullish, suggesting a potential for a short squeeze if the stock price starts to rise. NRXP's short interest is notably higher than its peer group average of 3.23%.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 2:15 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has developed a new, proprietary formulation of IV Ketamine, HTX-100, with a neutral pH, enabling both IV and subcutaneous administration. This development, based on prior patents by NRx's founder, may lead to patent protection and is expected to be marketed by HOPE Therapeutics, a subsidiary of NRx. The formulation was developed in partnership with Nephron Pharmaceuticals and is aimed at modernizing ketamine's use in medicine, potentially through insulin pump-like devices. NRx plans to submit a New Drug Application for HTX-100 for treating suicidal depression.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:34 pm

Trading for NRXP was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:50 pm

NRX Pharmaceuticals (NASDAQ:NRXP) reported Q4 earnings with losses of $(0.05) per share, surpassing the analyst consensus estimate of $(0.07) by 28.57%. This represents a 68.75% improvement over the $(0.16) per share loss from the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

March 29, 2024 | 3:34 am

NRx Pharmaceuticals has announced its preliminary results, projecting a fiscal year 2024 earnings per share (EPS) of $(0.40).

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.